<DOC>
	<DOCNO>NCT02247479</DOCNO>
	<brief_summary>This study Phase III , double-masked , multicenter , randomize , sham injection-controlled study evaluate efficacy safety lampalizumab administer intravitreal injection participant geographic atrophy ( GA ) secondary age-related macular degeneration ( AMD ) .</brief_summary>
	<brief_title>A Study Investigating Efficacy Safety Lampalizumab Intravitreal Injections Participants With Geographic Atrophy Secondary Age-Related Macular Degeneration ( CHROMA )</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>Participants age &gt; /= 50 year Well demarcate area ( ) GA secondary AMD evidence prior active choroidal neovascularization ( CNV ) eye Ocular Study Eye History vitrectomy surgery , submacular surgery , surgical intervention AMD Previous laser photocoagulation CNV , diabetic macular edema , retinal vein occlusion , proliferative diabetic retinopathy Previous intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection , antiangiogenic drug , anticomplement agent , device implantation ) Ocular Both Eyes GA either eye due cause AMD Previous treatment eculizumab , lampalizumab and/or fenretinide</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>